Trial Profile
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Parenterally Administered BVS857 in Healthy Subjects Without and With Insulin Resistance
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Apr 2015
Price :
$35
*
At a glance
- Drugs BVS 857 (Primary)
- Indications Insulin resistance
- Focus Pharmacodynamics
- Sponsors Novartis
- 12 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Sep 2011 New trial record